TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Before the recruitment of patients, the study was approved by Brazil Platform (a national and unified basis of research involving human subjects records) and published by the ClinicalTrials.gov~Inclusion Criteria:~* ASA I or II~* BMI between 18 and 29~Exclusion Criteria:~* Use of medications that could affect the neuromuscular blockade such as calcium channel inhibitors, anticonvulsants and lithium carbonate~* Presence of neuromuscular, renal or hepatic dysfunction.~* Hypermetabolic or hypometabolic states such as fever, infection, and hyperthyroidism or hypothyroidism~* Acid-base disorder, congestive heart failure or conductive heart problems, and those who were being treated for cardiac arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group M (Type: EXPERIMENTAL): Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds.
- Group ML (Type: EXPERIMENTAL): Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds
- Group C (Type: PLACEBO_COMPARATOR): Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Double-blind phase: DSM-IV diagnosis of schizophrenia for at least 1 year~* experiencing an acute episode, with a total PANSS score at screening between 70 and 120~* agree to voluntary hospitalization for a minimum of 14 days. Open-label phase: must have completed the 6 weeks of double-blind treatment or completed at least 21 days of treatment and discontinued due to lack of efficacy.~Exclusion Criteria:~* DSM-IV axis I diagnosis other than schizophrenia~* DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary)~* history of neuroleptic malignant syndrome (NMS)~* history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic)~* previous history of lack of response to risperidone when acutely psychotic~* significant risk of suicidal or violent behavior.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma on Osteoarthritis of Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 35 to 75 y/o.~2. Alert consciousness~3. Symptom of knee osteoarthritis persist at least 6 months and stage I or II scored by Ahlbäck grading system~4. The pain score measured by VAS at least 4 points~Exclusion Criteria:~1. Has received hyaluronic acid or steroid injection within 6 monts~2. Has received NSAIDs or steroid within one week~3. Tumor or metastasis surrounding the knee joint~4. Has received total knee replacement, major surgery in knee, rheumatoid arthritis~5. Patient who cant tolerance the balance or muscle strength test.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Platelet rich plasma (Type: ACTIVE_COMPARATOR): Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side.
- normal saline (Type: PLACEBO_COMPARATOR): Normal saline was injected into the other side of knee as the control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Visual impairment predominantly due to neovascular age-related macular degeneration AMD~* Active, newly diagnosed, untreated CNV due to AMD~* CNV involving the center of the retina~* A qualifying vision score at study entry~Exclusion Criteria:~* Stroke or myocardial infarction less than 3 Months prior to study entry~* Active injection or inflammation of either eye at the time of study entry

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBZ 0.5 mg: VA only (Group I) (Type: EXPERIMENTAL): RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
- RBZ 0.5 mg: VA and/or OCT (Group II) (Type: EXPERIMENTAL): RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).~* Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.~* Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.~Exclusion Criteria:~* History of known or suspected complete ankylosis of the spine.~* History of allergies, intolerance or hypersensitivity to lactose or tofacitinib.~* History of any other rheumatic disease.~* Any subject with condition affecting oral drug absorption.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo elective thyroidectomy under general anesthesia~* American Society of Anesthesiologists (ASA)physical classification I-II~* Willingness and ability to sign an informed consent document~Exclusion Criteria:~* American Society of Anesthesiologists (ASA)physical classification III or more~* BMI \> 40kg/m\^2~* Allergies to anesthetic or analgesic medications (benzodiazepines, propofol, remifentanil, fentanyl citrate, rocuronium bromide, sugammadex, flumazenil)~* Patients who receive mechanical ventilation morethan 2 hours after surgery~* Patients who receive the following medications within 24 hours prior to general anesthetics: anxiolytics, antipsychotics, rifampicin, succinycholine, neostigmine, flumazenil, cyclosporin~* Patients with galactose intolerance or Lapp Lactase deficiency or glucose-galactose malabsorption~* Medical or psychological disease that can affect the treatment response

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- remimazolam group (Type: EXPERIMENTAL): In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil 0.2mg, is administered at the end of surgery. In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
- propofol group (Type: ACTIVE_COMPARATOR): In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medical Therapy of Prostatic Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Peak urinary flow rate at least 4 ml/sec but not greater than 15 ml/sec; and voided volume is at least 125 ml.~* American Urological Association Symptom Score is greater than or equal to 8 and less than or equal to 30.~* Voluntarily signed the informed consent agreement prior to the performance of any study procedures.~Exclusion Criteria:~* Serum prostate specific antigen level greater than 10 ng/ml.~* Supine blood pressure less than 90/70 mmHG. Orthostatic hypotension.~* Any prior medical or surgical intervention for BPH.~* Received any prior experimental intervention (either medical or surgical) for prostate disease or enrolled in any other study protocol.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Doxazosin and Finasteride placebos
- Doxazosin (Type: EXPERIMENTAL): Doxazosin and Finasteride placebo
- Finasteride (Type: EXPERIMENTAL): Doxazosin placebo and Finasteride
- Combination (Type: EXPERIMENTAL): Doxazosin and Finasteride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 2 through 17 years of age~* Absolute Neutrophil Count (ANC) is below 500/microliter~* Have persistent fever (at least 4 days) despite antibiotic therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Require treatment for MF and classified at least as intermediate risk level 1 defined by the International Working Group.~* Platelet count \< 100x10 \^9/L at screening or at Study Day 1.~Exclusion Criteria:~* Received platelet transfusion within 14 days prior to Screening evaluations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stratum -1 (Type: EXPERIMENTAL): Participants with baseline Platelet counts of 75-99 x10\^9/L
- Stratum -2 (Type: EXPERIMENTAL): Participants with baseline Platelet counts of 50-74 x10\^9/L

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 18~* Pre- or post-menopausal women with Stage I and II breast cancer, triple negative tumors~* Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm~* Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (Tumors \< 5 mm in size do not require nodal assessment) or after mastectomy~* No previous chemotherapy~* Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document~Exclusion Criteria:~* Previous radiation therapy to the ipsilateral breast~* Active connective tissue disorders, such as lupus or scleroderma~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ChemoRT (Type: EXPERIMENTAL): Concurrent Carboplatin and Radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of noninfectious uveitis~* diagnosis of macular edema associated with noninfectious uveitis~Exclusion Criteria:~* any ocular trauma within the immediate 6 months prior to treatment~* any photocoagulation or cryotherapy in the 6 months prior to treatment~* any IVT injection of anti-VEGF treatment in the 2 months prior to treatment~* any eye diseases other than uveitis and ME that could compromise central visual acuity~* any previous suprachoroidal injection of triamcinolone acetonide in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 mg CLS-TA (Type: EXPERIMENTAL): Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
- 0.8 mg CLS-TA (Type: EXPERIMENTAL): Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obtention of a written informed consent.~* Patient over 18.~* Patient with histologically proved cholangiocarcinoma ; histologic diagnosis must be proved by biliary brushing, bile cytology, endobiliary biopsy under Spyglass, or by EUS-FNA.~* Patient with Karnofsky score ≥ 50 %~* Patient capable of fill in the quality of life questionnaire.~Exclusion Criteria:~* No written informed consent.~* Patients under or already treated by radiotherapy or chemotherapy treatment for cholangiocarcinoma.~* Patients with porphyria or hypersensibility to porphyrins.~* Pregnant, parturient or breastfeeding women.~* Patient under 18.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RFA+stent+S-1 (Type: EXPERIMENTAL): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
- RFA+stent (Type: PLACEBO_COMPARATOR): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has given written informed consent~* Subject has a diagnosis of moderate to severe chronic plaque psoriasis involving \>=10% with a Psoriasis Area and Severity Index (PASI) score \>=10 at Baseline~* Subject has CD4+ T lymphocyte (CD4) count at or above the lower limit of normal~* Male and female subjects must use an adequate means of contraception from screening to end of study.~Exclusion Criteria:~* Subject who received alefacept in the past~* Subject who has shown no improvement following an adequate course of nbUVB in the past~* Subject who has been treated in the past with either therapy or cyclosporine~* Subject with any active cancer, including skin cancer at Baseline~* Subject with erythrodermic, pustular or predominantly guttate psoriasis~* Subject who has used treatment for psoriasis prior to Baseline as follows:~  * Topical treatment within 14 days~ * Oral treatment within 28 days~ * Broad band UVB (bbUVB) or nbUVB treatment within 56 days~ * Biological treatment within 84 days~* Serious local infection or serious systemic infection within the 3 months prior to the first dose of study drug~* Subject with a history of drug or alcohol abuse within the past 2 years~* Subject that is known to be infected with the AIDS virus~* Subject with any other skin disease or other disease that might interfere with psoriasis status assessments~* Female subject who is nursing, pregnant or planning to become pregnant while in this study~* Subject who is currently enrolled in any other investigational drug or device study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alefacept alone (Type: ACTIVE_COMPARATOR): 15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
- Alefacept + nbUVB (Type: EXPERIMENTAL): 15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete